Compare PNBK & VRCA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PNBK | VRCA |
|---|---|---|
| Founded | 1999 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 105.9M | 88.0M |
| IPO Year | 2006 | 2018 |
| Metric | PNBK | VRCA |
|---|---|---|
| Price | $0.86 | $3.56 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $13.83 |
| AVG Volume (30 Days) | ★ 89.3K | 56.5K |
| Earning Date | 11-12-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 98.31 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $35,577,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $58.05 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 370.22 |
| 52 Week Low | $0.80 | $3.08 |
| 52 Week High | $19.95 | $9.82 |
| Indicator | PNBK | VRCA |
|---|---|---|
| Relative Strength Index (RSI) | 48.88 | 44.67 |
| Support Level | $0.80 | $3.19 |
| Resistance Level | $0.91 | $5.94 |
| Average True Range (ATR) | 0.05 | 0.31 |
| MACD | 0.01 | 0.07 |
| Stochastic Oscillator | 61.50 | 30.09 |
Patriot National Bancorp Inc provides consumer and commercial banking services to individuals, small and medium-sized businesses, professionals, and municipalities in Fairfield and New Haven Counties in Connecticut and Westchester County, New York. Its products include checking accounts, savings accounts, money market accounts, time certificates of deposit, and individual retirement accounts. The Bank's lending portfolio is comprised of commercial mortgage and construction loans, commercial loans, home improvement loans, home equity lines of credit, and other personal loans. In addition, the Bank offers bank checks, money orders, automated teller machines, interactive teller machines, online and mobile banking, credit cards, and debit cards.
Verrica Pharmaceuticals Inc is a therapeutics company developing and commercializing medications for the treatment of dermatologic diseases, including skin cancers. Its commercial product and portfolio of product candidates are clinician administered therapies in areas of high unmet need. This product portfolio consists of one product with an approved indication for molluscum contagiosum, or molluscum, with the potential for several follow-on indications, as well as additional pipeline product candidates. Its commercial product, YCANTH (VP-102), for the treatment of molluscum in adult and pediatric patients two years of age and older. YCANTH (VP-102) is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin.